Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women

JAMA

Volumn 304, Issue 15, 2010, Pages 1684-1692

  Chlebowski, Rowan T ^a   Anderson, Garnet L ^b   Gass, Margery ^c   Lane, Dorothy S ^d   Aragaki, Aaron K ^b   Kuller, Lewis H ^e   Manson, JoAnn E ^f   Stefanick, Marcia L ^g   Ockene, Judith ^h   Sarto, Gloria E ⁱ   Johnson, Karen C ^j   Wactawski Wende, Jean ^k   Ravdin, Peter M ^l   Schenken, Robert ^m   Hendrix, Susan L ⁿ   Rajkovic, Aleksandar ^o   Rohan, Thomas E ^p   Yasmeen, Shagufta ^q   Prentice, Ross L ^b  

^a UCLA MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF MASSACHUSETTS   (United States)

ⁱ UNIVERSITY OF WISCONSIN MADISON   (United States)

^j UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^k UNIVERSITY AT BUFFALO   (United States)

^l University of Texas Health Science Center at San Antonio   (United States)

^m UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁿ WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o BAYLOR COLLEGE OF MEDICINE   (United States)

^p ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DRUG COMBINATION;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ESTROGEN THERAPY; FEMALE; HAZARD RATIO; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGED; BREAST TUMOR; CANCER STAGING; CONTROLLED STUDY; DRUG COMBINATION; EPIDEMIOLOGY; FOLLOW UP; HORMONE SUBSTITUTION; INCIDENCE; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; TUMOR INVASION; UNITED STATES;

AGED; BREAST NEOPLASMS; DRUG COMBINATIONS; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; LYMPHATIC METASTASIS; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSTMENOPAUSE; PROGNOSIS; UNITED STATES;

EID: 77958138780     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1500     Document Type: Article

References (40)

1. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
2. Chlebowski RT, Hendrix SL, Langer RD, et al; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA. 2003;289(24):3243-3253.
3. Chlebowski RT, Anderson GL, Pettinger M, et al; Women's Health Initiative Investigators. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med. 2008;168(4):370-377.
4. Chlebowski RT, Kuller LH, Prentice RL, et al; WHI Investigators. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009;360(6):573-587.
5. Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol. 1998;16(9):3115-3120.
6. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer. 2004;101(7):1490-1500.
7. Rosenberg LU, Granath F, Dickman PW, et al. Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res. 2008;10(5):R78.
8. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419-427.
9. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol. 2003;21(23):4314-4321.
10. Newcomb PA, Egan KM, Trentham-Dietz A, et al. Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(4):864-871.
11. Christante D, Pommier S, Garreau J, Muller P, LaFleur B, Pommier R. Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up. Am J Surg. 2008;196(4):505-511.
12. Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19 (1):61-109.
13. Hays J, Hunt JR, Hubbell FA, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol. 2003;13(9)(suppl):S18-S77.
14. Anderson GL, Manson J, Wallace R, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol. 2003;13(9)(suppl):S5-S17.
15. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477.
16. Curb JD, McTiernan A, Heckbert SR, et al; WHI Morbidity and Mortality Committee. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003;13 (9)(suppl):S122-S128.
17. National Cancer Institute. Surveillance, Epidemiology, and End Results program. http://seer.cancer.gov/. Accessed September 24, 2009.
18. Sener SF, Winchester DJ, Winchester DP, et al. The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival. Am J Surg. 2009;197(3):403-407.
19. Heiss G, Wallace R, Anderson GL, et al; WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299(9):1036-1045.
20. Joffe MM, Byrne C, Colditz GA. Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias. Epidemiology. 2001;12(4):429-438. (Pubitemid 32566485)
21. Shen Y, Yang Y, Inoue LYT, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005;97(16):1195-1203.
22. Sihto H, Lundin J, Lehtimäki T, et al. Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res. 2008;14(13):4103-4110.
23. Dong W, Berry DA, Bevers TB, et al. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev. 2008;17(5):1096-1103.
24. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006; 24(33):e49-e50.
25. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670-1674.
26. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004; 291(1):47-53.
27. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25(25):3808-3815.
28. Chlebowski RT, Schwartz AG, Wakelee H, et al; Women's Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet. 2009; 374(9697):1243-1251.
29. Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol. 2001; 21(1):6-12.
30. Dobrzycka B, Kinalski M, Piechocka D, Terlikowski SJ. The role of estrogens in angiogenesis in the female reproductive system [in Polish]. Endokrynol Pol. 2009;60(3):210-214.
31. Liang Y, Besch-Williford C, Brekken RA, Hyder SM. Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res. 2007;67(20): 9929-9936.
32. Hyder SM, Murthy L, Stancel GM. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res. 1998;58(3):392-395. (Pubitemid 28087395)
33. Calvo A, Catena R, Noble MS, et al. Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene. 2008;27(40):5373-5384.
34. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med. 1991;324 (1):1-8.
35. Power ML, Anderson BL, Schulkin J. Attitudes of obstetrician- gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical. Menopause. 2009; 16(3):500-508.
36. Stevenson JC, Hodis HN, Pickar JH, Lobo RA. Coronary heart disease and menopause management: the swinging pendulum of HRT. Atherosclerosis. 2009; 207(2):336-340.
37. Toh S, Hernández-Díaz S, Logan R, Rossouw JE, Hernán MA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? a randomized trial. Ann Intern Med. 2010;152(4):211-217.
38. Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol. 2008;167(10):1207-1216.
39. Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol. 2009;27(31):5138-5143.
40. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006;55(2):103-115.